<p><em>新型抗 IL-31 单克隆抗体的分阶段推出现已开始，产品正在由部分早期体验项目的兽医在诊所中使用</em></p>
<ul>
<li>Befrena 对于治疗犬类过敏性皮炎和犬类特应性皮炎有效，没有年龄或体重限制，效果持续 6 到 8 周，而目前市场上的竞争产品 lokivetmab 仅为 4 到 8 周</li>
<li>在 24 小时内开始控制瘙痒，并作为诊所内注射给药</li>
<li>部分早期体验项目的兽医已经在临床实践中使用 Befrena，并看到积极的效果</li>
<li>认识 Beaux、Penelope 和 Zephyr，这三只首批接受 Befrena 治疗的早期体验患者，关注它们的瘙痒缓解之旅</li>
<li>Befrena 是 Elanco 在美国宠物健康市场推出的第二款单克隆抗体，加入了 Trutect™，这是唯一获得批准的治疗犬类细小病毒的治疗方案，并已被证明对被动免疫有效</li>
</ul>
<p>, /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) 今天宣布推出 Befrena™ (tirnovetmab)，这是一种用于治疗犬类过敏性和特应性皮炎的新型抗 IL-31 单克隆抗体 (mAb) 注射剂。此次推出恰逢关键时刻，预计今年全国将迎来更长且更严重的过敏季节。近 2/3 的瘙痒犬在过敏季节经历更严重的瘙痒，Befrena 通过提供一种在 24 小时内开始控制过敏性瘙痒的新治疗选择，扩展了 Elanco 的皮肤病学产品组合。通过中和 IL-31 这一关键细胞因子，Befrena 提供了 6 到 8 周的给药间隔，为兽医和宠物主人提供了新的便利和疗效。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2981460/Elanco_Beaux_before_receiving_his_first_Befrena_injection.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2981460/Elanco_Beaux_before_receiving_his_first_Befrena_injection.jpg"/></p>
<p>Befrena 的好处：</p>
<ul>
<li>提供至少 6 到 8 周的瘙痒缓解，而目前市场上的竞争产品 lokivetmab 仅为 4 到 8 周</li>
<li>在 24 小时内开始控制瘙痒</li>
<li>作为由持证兽医施用或在其监督下进行的诊所内注射给药</li>
</ul>
<p>Elanco 于 2025 年 12 月获得美国农业部 (USDA) 对 Befrena 的批准，使其成为公司在过去两年中获得批准并推出的第二款皮肤病学产品，另有 Zenrelia™ (ilunocitinib 片剂)。</p>
<p>Elanco 现在也是唯一拥有两款美国农业部批准的 mAb 产品的宠物健康公司——Befrena 和 Trutect。Trutect 是唯一获得批准的治疗犬类细小病毒的治疗方案。</p>
<p>&#34;Befrena 在 13 亿美元的美国犬类皮肤病市场的商业推出是我们创新旅程中的另一个激动人心的里程碑，&#34; Elanco 美国宠物健康及全球数字转型执行副总裁 Bobby Modi 表示。&#34;我们看到早期体验项目的兽医在其诊所中开始使用 Befrena 并取得积极成果，我们将继续增加这种新型单克隆抗体的供应，同时随着预期的生产能力提升扩大我们的生物反应器。&#34;</p>
<p><strong>让最好的朋友更好——认识首批接受 Befrena 治疗的狗狗</strong></p>
<p>根据宠物主人，近 90% 的美国狗狗被称为 “瘙痒狗”，在一年中的任何时候都经历过瘙痒症状。Elanco 的《美国瘙痒狗报告》中的数据显示，兽医表示，瘙痒狗的主人在带狗狗就医前等待的时间过长，导致狗狗皮肤受损和感染，主人也希望狗狗能尽快得到缓解。</p>
<p>作为 Befrena 早期体验项目的一部分，部分兽医和兽医皮肤科医生已经开始在其诊所中使用 Befrena，并看到瘙痒狗的初步改善。</p>
<p>来自德克萨斯州奥斯汀的 Beaux 是第一只接受 Befrena 治疗的狗狗，因持续瘙痒而经历了显著的脱毛。</p>
<p>根据德克萨斯州奥斯汀的 Liberty Animal Hospital 的 Matt Lane 博士在 Beaux 的三周复查时表示，&#34;Beaux 的情况非常好，他的主人很高兴看到他的毛发开始长回来了。他在接受注射后 24 小时内停止了瘙痒，我和他的主人对结果非常满意。&#34;</p>
<p>Penelope 和 Zephyr 也在俄亥俄州哥伦布的 Gigi's 动物收容所接受了 Befrena 治疗。这两只狗都经历了影响其行为和生活质量的季节性过敏，在与兽医讨论后，两位主人选择了 Befrena 来控制狗狗的瘙痒。</p>
<p>&#34;我们希望让这些狗狗得到缓解，并确保它们有尽可能舒适的体验，我认为 Befrena 在这方面展现了真正的潜力，&#34; Gigi's 的行为、研究和教育高级主任 Meghan Herron 博士表示。</p>
<p>Zephyr 的主人也是 Gigi's 的持证兽医技术员，帮助施用 Zephyr 的注射。您可以关注它们的旅程。</p>
<p>https://elanco.wistia.com/medias/5nbmg3s2hk</p>
<p>&#34;我参与了两个临床试验和早期体验项目，这表明 Befrena 是一种高度安全和有效的产品，&#34; 皮肤科兽医、动物皮肤病学诊所创始人 Tom Lewis 博士表示。&#34;这将成为许多过敏狗的重要治疗选择，我很高兴在我的诊所中使用 Befrena。&#34;*</p>
<p>&#34;到目前为止，我在几个患者身上使用了 Befrena，虽然仍然相对较早，但我对这些病例的结果非常乐观和兴奋，&#34; 爱荷华州立大学兽医学院皮肤科终身副教授 Jason Pieper 博士表示。&#34;我有几个患者反应非常好，包括一个在多种其他特应性皮炎治疗中失败的独特病例。到目前为止，在接受 Befrena 治疗两周后，这只狗的情况相当不错，真是太棒了。&#34;*</p>
<p>了解更多关于 Befrena 的信息，并注册以获取未来的新闻和网络研讨会，访问 www.befrenaforvets.com。</p>
<p>*Pieper 博士和 Lewis 博士是 Elanco 的顾问。</p>
<p><strong>关于 Elanco</strong> Elanco Animal Health Incorporated（纽约证券交易所代码：ELAN）是全球动物健康领域的领导者，致力于创新和提供产品与服务，以预防和治疗农场动物和宠物的疾病，为农民、宠物主人、兽医、利益相关者和整个社会创造价值。凭借 70 年的动物健康传统，我们致力于打破界限，超越自我，帮助客户改善他们所照顾动物的健康，同时对我们当地和全球社区产生有意义的影响。在 Elanco，我们的愿景是 “食物与陪伴丰富生活”，我们的使命是——为动物、客户、社会和我们的员工超越一切。了解更多信息，请访问 www.elanco.com。</p>
<p><strong>适应症</strong></p>
<p>Zenrelia 是一种处方药，用于控制与皮肤过敏相关的瘙痒和炎症，适用于 12 个月以上的狗。</p>
<p><strong>重要安全信息</strong></p>
<p><strong>在使用此药物之前，请阅读包装说明书，包括黑框警告。</strong> 有关完整的处方信息，请咨询您的兽医，拨打 1 888 545 5973 或访问 <strong>www.elancolabels.com/us/zenrelia</strong>。</p>
<p><strong>警告：对疫苗的免疫反应不足。根据疫苗反应研究的结果，接受 Zenrelia 的狗在疫苗接种时面临免疫反应不足的风险。在接种疫苗前至少 28 天至 3 个月停止使用 Zenrelia，并在接种疫苗后至少 28 天内暂停使用 Zenrelia。</strong> 狗在开始使用 Zenrelia 之前应确保疫苗接种是最新的。不得用于 12 个月以下的狗或有严重感染的狗。应监测狗的感染情况，因为 Zenrelia 可能增加感染的风险。在临床研究中观察到肿瘤性疾病（良性和恶性）。最常见的副作用包括呕吐、腹泻和疲劳。Zenrelia 尚未在用于繁殖的狗、怀孕或哺乳的狗中进行测试，也未与糖皮质激素、环孢素或其他免疫抑制药物联合评估。</p>
<p>Befrena、Zenrelia、Trutect、Elanco 及其对角线标志是 Elanco 或其附属公司的商标。© 2026 Elanco 或其附属公司</p>
<p><strong>PM-US-26-0849</strong></p>
<p>i 美国哮喘与过敏基金会，（2026）。2026 年过敏资本。取自 allergycapitals.org。</p>
<p>ii Elanco Animal Health。档案数据。REF-28442</p>
<p>iii Elanco Animal Health。档案数据。REF-29772</p>
<p>投资者联系：Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com</p>
<p>媒体联系：Season Solorio (765) 316-0233 season.solorio@elancoah.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2981461/Elanco_Beaux_after_receiving_his_first_Befrena_injection.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2981461/Elanco_Beaux_after_receiving_his_first_Befrena_injection.jpg"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2309278/Elanco_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2309278/Elanco_Logo.jpg"/></p>
<p>来源 Elanco Animal Health</p>

ELAN

<p>Elanco Animal Health 推出了 Befrena™（tirnovetmab），这是一种用于治疗犬类过敏性皮肤炎的新型抗 IL-31 单克隆抗体。该产品提供 6 到 8 周的止痒效果，并在 24 小时内开始发挥作用，目前正在由部分兽医使用。这次推出扩展了 Elanco 在 13 亿美元的美国犬类皮肤病市场中的皮肤病产品组合，此前已获得美国农业部的批准。兽医的早期结果显示，患有过敏的狗狗有积极的治疗效果</p>

<p><em>Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today</em></p>
<div class="lb-trans"><p><em>新型抗 IL-31 单克隆抗体的分阶段推出现已开始，产品正在由部分早期体验项目的兽医在诊所中使用</em></p>
</div><ul>
<li>Befrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmab</li>
<li>Starts controlling itch within 24 hours and is given as an in-clinic injection</li>
<li>Select Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomes</li>
<li>Meet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their journeys to itch relief</li>
<li>Befrena is Elanco's second monoclonal antibody to launch in the U.S. pet health market, joining Trutect™, the first and only approved therapeutic solution to treat canine parvovirus and has been shown to be effective for passive immunity</li>
</ul>
<div class="lb-trans"><ul>
<li>Befrena 对于治疗犬类过敏性皮炎和犬类特应性皮炎有效，没有年龄或体重限制，效果持续 6 到 8 周，而目前市场上的竞争产品 lokivetmab 仅为 4 到 8 周</li>
<li>在 24 小时内开始控制瘙痒，并作为诊所内注射给药</li>
<li>部分早期体验项目的兽医已经在临床实践中使用 Befrena，并看到积极的效果</li>
<li>认识 Beaux、Penelope 和 Zephyr，这三只首批接受 Befrena 治疗的早期体验患者，关注它们的瘙痒缓解之旅</li>
<li>Befrena 是 Elanco 在美国宠物健康市场推出的第二款单克隆抗体，加入了 Trutect™，这是唯一获得批准的治疗犬类细小病毒的治疗方案，并已被证明对被动免疫有效</li>
</ul>
</div><p>, /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the phased launch of Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody (mAb) injection for treatment of canine allergic and atopic dermatitis. The launch comes at a key time, with a longer and more intense allergy season anticipated across the country this year.i With nearly 2 in 3 itchy dogs experiencing worse itch during allergy seasonii, Befrena expands Elanco's dermatology portfolio by offering a new treatment option that starts controlling allergic itch within 24 hours. By neutralizing IL-31, a key cytokine involved in sending itch signals to the brain, Befrena offers a differentiated 6 to 8 weeks dosing interval, providing veterinarians and pet owners with a new level of convenience and efficacy.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) 今天宣布推出 Befrena™ (tirnovetmab)，这是一种用于治疗犬类过敏性和特应性皮炎的新型抗 IL-31 单克隆抗体 (mAb) 注射剂。此次推出恰逢关键时刻，预计今年全国将迎来更长且更严重的过敏季节。近 2/3 的瘙痒犬在过敏季节经历更严重的瘙痒，Befrena 通过提供一种在 24 小时内开始控制过敏性瘙痒的新治疗选择，扩展了 Elanco 的皮肤病学产品组合。通过中和 IL-31 这一关键细胞因子，Befrena 提供了 6 到 8 周的给药间隔，为兽医和宠物主人提供了新的便利和疗效。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2981460/Elanco_Beaux_before_receiving_his_first_Befrena_injection.jpg" alt="" original-src="https://mma.prnewswire.com/media/2981460/Elanco_Beaux_before_receiving_his_first_Befrena_injection.jpg"/></p>
<p>Benefits of Befrena:</p>
<div class="lb-trans"><p>Befrena 的好处：</p>
</div><ul>
<li>Offers at least 6 to 8 weeks of itch relief, in contrast to the 4 to 8 weeks of the current market incumbent, lokivetmab</li>
<li>Starts controlling itch within 24 hours</li>
<li>Given as an in-clinic injection administered by, or under the supervision of, a licensed veterinarian</li>
</ul>
<div class="lb-trans"><ul>
<li>提供至少 6 到 8 周的瘙痒缓解，而目前市场上的竞争产品 lokivetmab 仅为 4 到 8 周</li>
<li>在 24 小时内开始控制瘙痒</li>
<li>作为由持证兽医施用或在其监督下进行的诊所内注射给药</li>
</ul>
</div><p>Elanco received approval of Befrena from the U.S. Department of Agriculture (USDA) in December 2025, making it the company's second dermatology product, alongside Zenrelia™ (ilunocitinib tablets), to be approved and launched in the past two years.</p>
<div class="lb-trans"><p>Elanco 于 2025 年 12 月获得美国农业部 (USDA) 对 Befrena 的批准，使其成为公司在过去两年中获得批准并推出的第二款皮肤病学产品，另有 Zenrelia™ (ilunocitinib 片剂)。</p>
</div><p>Elanco is also now the only pet health company with two USDA approved mAb products – Befrena and Trutect. Trutect is the first and only approved therapeutic solution to treat canine parvovirus.</p>
<div class="lb-trans"><p>Elanco 现在也是唯一拥有两款美国农业部批准的 mAb 产品的宠物健康公司——Befrena 和 Trutect。Trutect 是唯一获得批准的治疗犬类细小病毒的治疗方案。</p>
</div><p>&#34;The commercial launch of Befrena into the $1.3 billion U.S. canine dermatology marketiii is another exciting milestone in our innovation journey,&#34; said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. &#34;We are seeing positive results from our Early Experience Program veterinarians who have started using Befrena in their clinics and will continue to increase supply of this new monoclonal antibody, as we scale our bioreactors with the anticipated manufacturing ramp-up.&#34;</p>
<div class="lb-trans"><p>&#34;Befrena 在 13 亿美元的美国犬类皮肤病市场的商业推出是我们创新旅程中的另一个激动人心的里程碑，&#34; Elanco 美国宠物健康及全球数字转型执行副总裁 Bobby Modi 表示。&#34;我们看到早期体验项目的兽医在其诊所中开始使用 Befrena 并取得积极成果，我们将继续增加这种新型单克隆抗体的供应，同时随着预期的生产能力提升扩大我们的生物反应器。&#34;</p>
</div><p><strong>Make Best Friends Better – Meet the First Dogs Treated with Befrena</strong></p>
<div class="lb-trans"><p><strong>让最好的朋友更好——认识首批接受 Befrena 治疗的狗狗</strong></p>
</div><p>Nearly 9 in 10 dogs in the U.S. are &#34;itchy dogs&#34; according to their pet owners, having experienced symptoms of itch at any point throughout the yearii. Data in Elanco's America's Itchy Dogs Report also found that veterinarians say that itchy dog owners wait too long before bringing in their dog, resulting in raw and infected skin and an irritated dog owner who wants their dog to experience relief quickly.ii</p>
<div class="lb-trans"><p>根据宠物主人，近 90% 的美国狗狗被称为 “瘙痒狗”，在一年中的任何时候都经历过瘙痒症状。Elanco 的《美国瘙痒狗报告》中的数据显示，兽医表示，瘙痒狗的主人在带狗狗就医前等待的时间过长，导致狗狗皮肤受损和感染，主人也希望狗狗能尽快得到缓解。</p>
</div><p>As a part of the Befrena Early Experience Program, select veterinarians and veterinary dermatologists have already started using Befrena in their clinics and seen initial improvements in itchy dogs.</p>
<div class="lb-trans"><p>作为 Befrena 早期体验项目的一部分，部分兽医和兽医皮肤科医生已经开始在其诊所中使用 Befrena，并看到瘙痒狗的初步改善。</p>
</div><p>Beaux from Austin, TX was the first dog treated with Befrena after experiencing significant hair loss due to his constant itch.</p>
<div class="lb-trans"><p>来自德克萨斯州奥斯汀的 Beaux 是第一只接受 Befrena 治疗的狗狗，因持续瘙痒而经历了显著的脱毛。</p>
</div><p>According to Dr. Matt Lane at Liberty Animal Hospital at Beaux's 3-week checkup appointment, &#34;Beaux is doing amazing, and his owner is excited to see his hair growing back. He stopped itching within 24 hours of receiving the injection and his owner and I are extremely pleased with the results.&#34;</p>
<div class="lb-trans"><p>根据德克萨斯州奥斯汀的 Liberty Animal Hospital 的 Matt Lane 博士在 Beaux 的三周复查时表示，&#34;Beaux 的情况非常好，他的主人很高兴看到他的毛发开始长回来了。他在接受注射后 24 小时内停止了瘙痒，我和他的主人对结果非常满意。&#34;</p>
</div><p>Penelope and Zephyr were also treated with Befrena at Gigi's Animal Shelter in Columbus, OH. Both dogs experience seasonal allergies that impact their behavior and quality of life and after discussing with their veterinarian both owners chose Befrena to control their dogs' itch.</p>
<div class="lb-trans"><p>Penelope 和 Zephyr 也在俄亥俄州哥伦布的 Gigi's 动物收容所接受了 Befrena 治疗。这两只狗都经历了影响其行为和生活质量的季节性过敏，在与兽医讨论后，两位主人选择了 Befrena 来控制狗狗的瘙痒。</p>
</div><p>&#34;We want to get these dogs relief and make sure they have the most comfortable experience as possible, and I think Befrena shows some real promise for that,&#34; said Dr. Meghan Herron, Senior Director of Behavior, Research, and Education at Gigi's.</p>
<div class="lb-trans"><p>&#34;我们希望让这些狗狗得到缓解，并确保它们有尽可能舒适的体验，我认为 Befrena 在这方面展现了真正的潜力，&#34; Gigi's 的行为、研究和教育高级主任 Meghan Herron 博士表示。</p>
</div><p>Zephyr's owner is also a licensed veterinary technician at Gigi's and helped administer Zephyr's injection. You can follow along their journey below.</p>
<div class="lb-trans"><p>Zephyr 的主人也是 Gigi's 的持证兽医技术员，帮助施用 Zephyr 的注射。您可以关注它们的旅程。</p>
</div><p>https://elanco.wistia.com/medias/5nbmg3s2hk</p>
<div class="lb-trans"><p>https://elanco.wistia.com/medias/5nbmg3s2hk</p>
</div><p>&#34;I have been involved with two clinical trials and the Early Experience Program which has shown Befrena to be a highly safe and effective product,&#34; said Dr. Tom Lewis, veterinary dermatologist and founder of Dermatology for Animals, a group of veterinary dermatology clinics committed to caring for pets with allergies. &#34;This will become a very important treatment option for many allergic dogs and I am excited to use Befrena in my clinic.&#34;*</p>
<div class="lb-trans"><p>&#34;我参与了两个临床试验和早期体验项目，这表明 Befrena 是一种高度安全和有效的产品，&#34; 皮肤科兽医、动物皮肤病学诊所创始人 Tom Lewis 博士表示。&#34;这将成为许多过敏狗的重要治疗选择，我很高兴在我的诊所中使用 Befrena。&#34;*</p>
</div><p>&#34;I've used Befrena in a few patients so far and while it's still relatively early, I'm very optimistic and excited about what's going to happen with these cases,&#34; said Dr. Jason Pieper, veterinary dermatologist and tenured associate professor of dermatology at Iowa State University College of Veterinary Medicine. &#34;I've had several patients respond very well including one unique case that has failed multiple other treatments for atopic dermatitis. And so far, two weeks after receiving Befrena, this dog's doing quite well, it's wonderful.&#34;*</p>
<div class="lb-trans"><p>&#34;到目前为止，我在几个患者身上使用了 Befrena，虽然仍然相对较早，但我对这些病例的结果非常乐观和兴奋，&#34; 爱荷华州立大学兽医学院皮肤科终身副教授 Jason Pieper 博士表示。&#34;我有几个患者反应非常好，包括一个在多种其他特应性皮炎治疗中失败的独特病例。到目前为止，在接受 Befrena 治疗两周后，这只狗的情况相当不错，真是太棒了。&#34;*</p>
</div><p>Learn more about Befrena and sign up for future news and webinars at www.befrenaforvets.com.</p>
<div class="lb-trans"><p>了解更多关于 Befrena 的信息，并注册以获取未来的新闻和网络研讨会，访问 www.befrenaforvets.com。</p>
</div><p>*Drs. Pieper and Lewis are consultants for Elanco.</p>
<div class="lb-trans"><p>*Pieper 博士和 Lewis 博士是 Elanco 的顾问。</p>
</div><p><strong>ABOUT ELANCO</strong> Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.</p>
<div class="lb-trans"><p><strong>关于 Elanco</strong> Elanco Animal Health Incorporated（纽约证券交易所代码：ELAN）是全球动物健康领域的领导者，致力于创新和提供产品与服务，以预防和治疗农场动物和宠物的疾病，为农民、宠物主人、兽医、利益相关者和整个社会创造价值。凭借 70 年的动物健康传统，我们致力于打破界限，超越自我，帮助客户改善他们所照顾动物的健康，同时对我们当地和全球社区产生有意义的影响。在 Elanco，我们的愿景是 “食物与陪伴丰富生活”，我们的使命是——为动物、客户、社会和我们的员工超越一切。了解更多信息，请访问 www.elanco.com。</p>
</div><p><strong>INDICATIONS</strong></p>
<div class="lb-trans"><p><strong>适应症</strong></p>
</div><p>Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age.</p>
<div class="lb-trans"><p>Zenrelia 是一种处方药，用于控制与皮肤过敏相关的瘙痒和炎症，适用于 12 个月以上的狗。</p>
</div><p><strong>IMPORTANT SAFETY INFORMATION</strong></p>
<div class="lb-trans"><p><strong>重要安全信息</strong></p>
</div><p><strong>Read the package insert, including the Boxed Warning, before using this drug.</strong> For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit <strong>www.elancolabels.com/us/zenrelia</strong>.</p>
<div class="lb-trans"><p><strong>在使用此药物之前，请阅读包装说明书，包括黑框警告。</strong> 有关完整的处方信息，请咨询您的兽医，拨打 1 888 545 5973 或访问 <strong>www.elancolabels.com/us/zenrelia</strong>。</p>
</div><p><strong>WARNING: INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of an inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination.</strong> Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs.</p>
<div class="lb-trans"><p><strong>警告：对疫苗的免疫反应不足。根据疫苗反应研究的结果，接受 Zenrelia 的狗在疫苗接种时面临免疫反应不足的风险。在接种疫苗前至少 28 天至 3 个月停止使用 Zenrelia，并在接种疫苗后至少 28 天内暂停使用 Zenrelia。</strong> 狗在开始使用 Zenrelia 之前应确保疫苗接种是最新的。不得用于 12 个月以下的狗或有严重感染的狗。应监测狗的感染情况，因为 Zenrelia 可能增加感染的风险。在临床研究中观察到肿瘤性疾病（良性和恶性）。最常见的副作用包括呕吐、腹泻和疲劳。Zenrelia 尚未在用于繁殖的狗、怀孕或哺乳的狗中进行测试，也未与糖皮质激素、环孢素或其他免疫抑制药物联合评估。</p>
</div><p>Befrena, Zenrelia, Trutect, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2026 Elanco or its affiliates</p>
<div class="lb-trans"><p>Befrena、Zenrelia、Trutect、Elanco 及其对角线标志是 Elanco 或其附属公司的商标。© 2026 Elanco 或其附属公司</p>
</div><p><strong>PM-US-26-0849</strong></p>
<div class="lb-trans"><p><strong>PM-US-26-0849</strong></p>
</div><p>i Asthma and Allergy Foundation of America, (2026). 2026 Allergy Capitals. Retrieved from allergycapitals.org.</p>
<div class="lb-trans"><p>i 美国哮喘与过敏基金会，（2026）。2026 年过敏资本。取自 allergycapitals.org。</p>
</div><p>ii Elanco Animal Health. Data on File. REF-28442</p>
<div class="lb-trans"><p>ii Elanco Animal Health。档案数据。REF-28442</p>
</div><p>iii Elanco Animal Health. Data on File. REF-29772</p>
<div class="lb-trans"><p>iii Elanco Animal Health。档案数据。REF-29772</p>
</div><p>Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com</p>
<div class="lb-trans"><p>投资者联系：Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com</p>
</div><p>Media Contact: Season Solorio (765) 316-0233 season.solorio@elancoah.com</p>
<div class="lb-trans"><p>媒体联系：Season Solorio (765) 316-0233 season.solorio@elancoah.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2981461/Elanco_Beaux_after_receiving_his_first_Befrena_injection.jpg" alt="" original-src="https://mma.prnewswire.com/media/2981461/Elanco_Beaux_after_receiving_his_first_Befrena_injection.jpg"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2309278/Elanco_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2309278/Elanco_Logo.jpg"/></p>
<p>SOURCE Elanco Animal Health</p>
<div class="lb-trans"><p>来源 Elanco Animal Health</p>
</div>

Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market | ELAN Stock News

Elanco 推出 Befrena™（tirnovetmab），这是一种新的抗 IL-31 单克隆抗体，为价值 13 亿美元的美国犬类皮肤病市场带来了突破性的新产品 | ELAN 股票新闻